BAVA Bavarian Nordic A/S

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, March 2, 2023 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such, which are hereby reported in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523.

The transactions concern the award of restricted stock units (RSUs) including matching shares to members of the Company’s Executive Management in accordance with a decision today by the Board of Directors to defer 50% of the annual cash bonus related to Executive Management’s performance in 2022 by conversion into RSUs. The RSUs and matching shares will vest in three years from the date of grant, provided that all vesting conditions have been met.

1.Details of the person discharging managerial responsibilities/person closely associated  
a)NamePaul Chaplin
2.Reason for the notification
a)Position/status



 
President and Chief Executive Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Restricted Stock Units





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 151.5510,642
d)Aggregated information
  • Aggregated volume
  • Price
 



10,642

DKK 1,612,821.00
e)Date of the transaction2023-03-02
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameHenrik Juuel
2.Reason for the notification
a)Position/status



 
Executive Vice President and Chief Financial Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Restricted Stock Units





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 151.545,748
d)Aggregated information
  • Aggregated volume
  • Price
 



5,748

DKK 871,062.00
e)Date of the transaction2023-03-02
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameJean-Christophe May
2.Reason for the notification
a)Position/status



 
Executive Vice President and Chief Commercial Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Restricted Stock Units





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 151.535,184
d)Aggregated information
  • Aggregated volume
  • Price
 



5,184

DKK 785,551.00
e)Date of the transaction2023-03-02
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameLaurence De Moerlooze
2.Reason for the notification
a)Position/status



 
Executive Vice President and Chief Medical Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Restricted Stock Units





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 151.594,981
d)Aggregated information
  • Aggregated volume
  • Price
 



4,981

DKK 755,057.00
e)Date of the transaction2023-03-02
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameAnu Helena Kerns
2.Reason for the notification
a)Position/status



 
Executive Vice President and Chief People Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Restricted Stock Units





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 151.523,450
d)Aggregated information
  • Aggregated volume
  • Price
 



3,450

DKK 552,750.00
e)Date of the transaction2023-03-02
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameRussell Thirsk
2.Reason for the notification
a)Position/status



 
Executive Vice President and Chief Operating Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Restricted Stock Units





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 151.573,637
d)Aggregated information
  • Aggregated volume
  • Price
 



3,637

DKK 551,250.00
e)Date of the transaction2023-03-02
f)Place of the transactionOutside a trading venue

About Bavarian Nordic

Bavarian Nordic is a fully integrated vaccines company focused on the research and development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox and mpox vaccines, which have been developed through our long-standing partnership with the U.S. Government to enhance public health preparedness. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, and in-licensed technologies, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including Phase 3 development programs for an RSV vaccine for older adults and a next-generation COVID-19 vaccine. For more information visit .

Contacts

Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel:

US: Graham Morrell, Paddock Circle Advisors, , Tel:

Company Announcement no. 09 / 2023

Attachment



EN
02/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bavarian Nordic A/S

 PRESS RELEASE

Paul Chaplin fratræder som administrerende direktør i Bavarian Nordic

Paul Chaplin fratræder som administrerende direktør i Bavarian Nordic KØBENHAVN, Danmark, 2. marts 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag, at bestyrelsen har indgået en aftale med administrerende direktør, Paul Chaplin, som ønsker at træde tilbage af personlige årsager. Paul Chaplin vil fortsætte i sin rolle indtil udgangen af 2026 eller indtil en efterfølger er identificeret. Bestyrelsen har igangsat processen med at identificere en ny administrerende direktør. Paul Chaplin har været hos Bavarian Nordic siden 1999 og blev udnævnt til administrerende direktør i 2014....

 PRESS RELEASE

Paul Chaplin Steps Down as CEO of Bavarian Nordic

Paul Chaplin Steps Down as CEO of Bavarian Nordic COPENHAGEN, Denmark, March 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today, that the Board of Directors has entered into an agreement with CEO, Paul Chaplin, who wishes to step down for personal reasons. Paul Chaplin will continue in his role for the remainder of 2026, or until a successor has been identified. The Board of Directors has initiated the process to identify a new CEO. Paul Chaplin has been with Bavarian Nordic since 1999 and was appointed CEO in 2014. He has led the development of the Company’s smallpox and mpox vacci...

 PRESS RELEASE

Bavarian Nordic offentliggør foreløbige resultater for 2025 og forvent...

Bavarian Nordic offentliggør foreløbige resultater for 2025 og forventninger til 2026 Resultatet overgår de seneste forventninger til 2025 efter en stærk udvikling i begge kommercielle forretningsben, Travel Health og Public Preparedness.Forventningerne til 2026 afspejler en fortsat vækst i Travel Health (10% fra egne produkter, 14% i konstant valuta) og et normaliseret år inden for Public Preparedness, begge områder i overensstemmelse med selskabets offentliggjorte vækstambitioner på mellemlang sigt. KØBENHAVN, Danmark, 12. februar 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i ...

 PRESS RELEASE

Bavarian Nordic Reports Preliminary 2025 Financial Results and Provide...

Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026 Exceeding latest 2025 guidance following a strong performance from both commercial arms of the business in Travel Health and Public Preparedness.2026 guidance reflects continued growth in Travel Health (10% from own products, 14% at constant exchange rates) and a normalized year in Public Preparedness, both in line with the communicated mid-term growth ambitions. COPENHAGEN, Denmark, February 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced preliminary, unaudited financial results for 2025 a...

 PRESS RELEASE

Bavarian Nordic – afslutning af aktietilbagekøbsprogram

Bavarian Nordic – afslutning af aktietilbagekøbsprogram KØBENHAVN, Danmark, 9. februar 2026 – Bavarian Nordic A/S (OMX: BAVA) meddeler, at aktietilbagekøbsprogrammet, der blev offentliggjort og iværksat den 7. januar 2026, nu er afsluttet, da aktier til en samlet værdi af ca. DKK 150 mio. er tilbagekøbt som planlagt. Dette udgjorde den første del af et samlet planlagt aktietilbagekøb på op til DKK 500 mio. i løbet af 2026. Bavarian Nordic vil beholde de tilbagekøbte aktier som egne aktier med det formål at tilpasse kapitalstrukturen. Programmet blev gennemført i overensstemmelse med bestem...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch